Nanoveu Ltd’s (ASX:NVU) shares have been almost 18% higher to 9 cents after signing distribution agreements for its antiviral protection products for the Thai and Malaysian markets with Sanyo Trading Company Ltd.
Through these agreements, Sanyo will look to leverage its extensive contacts in the Asia-Pacific region to distribute several Nanoveu’s products to groups including hospitals, banks, schools and shopping malls.
Nanoveu will ship its business to business (B2B) rolls of antiviral film – to be applied to an increasing number of surfaces – in addition to its consumer-focused antiviral mobile phone cases and door handles.
"Proud" to be a partner
Executive chairman and CEO Alfred Chong said: “Founded in 1947, Sanyo is a name that many consumers in the region are familiar with.
“We are proud that we have been elected to be a partner for such a reputable company which possesses both the reach and capability to distribute our products internationally.”
Highly effective technology
The company’s antiviral technology has been independently demonstrated to be a highly effective agent for the eradication of viruses.
It has been proven to eliminate 99.99%1 of OC43, a viral strain affecting humans that is also a surrogate for COVID-19, in 30 minutes.
The antiviral protection has also been validated against other bacteria and viruses including e.Coli, Influenza A (subtype H3N2), and coronavirus MHV-A592 .
Sanyo sales director Sandy Yew said: “The spread of disease is a major focus for many countries, including those in the Asia-Pacific region.
“We are excited about brining Nanoveu’s Nanoshield products to our customers, partners and distributors as it represents a credible and proven method of stemming the spread of harmful viruses and bacteria.”